NCT06835569 2026-03-09
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
Phase 1 Recruiting
Clinical Trials
82 trialsNCT05873686 2026-03-03
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Phase 1 Recruiting
NCT06959706 2026-02-20
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Tagworks Pharmaceuticals BV
Phase 1 Recruiting
NCT05068102 2026-02-18
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT07127874 2026-02-03
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Phase 1 Recruiting
NCT04752215 2026-02-02
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
Boehringer Ingelheim
Phase 1 Completed
NCT06457997 2026-01-29
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
Phase 1 Terminated
NCT05165433 2025-12-16
FORTIFY
Akamis Bio
Phase 1 Completed
NCT02592577 2025-12-09
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
Adaptimmune
Phase 1 Completed
NCT05768932 2025-10-15
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
Phase 1 Recruiting
NCT04603287 2025-09-26
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT05226507 2025-08-08
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Nuvectis Pharma, Inc.
Phase 1 Active not recruiting
NCT04053283 2025-03-24
STAR
Akamis Bio
Phase 1 Completed
NCT05043714 2025-03-24
NEBULA
Akamis Bio
Phase 1 Completed
NCT06069570 2025-03-05
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Kiromic BioPharma Inc.
Phase 1 Recruiting
NCT04862780 2025-02-10
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT05241873 2025-02-10
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
Phase 1 Terminated
NCT02834611 2024-05-29
Ceramide NanoLiposome in Patients With Advanced Solid Tumors
Keystone Nano, Inc
Phase 1 Completed
NCT02164461 2024-05-20
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Advaxis, Inc.
Phase 1 Completed
NCT02867007 2024-04-25
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT00728390 2024-04-22
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
Pfizer
Phase 1 Completed
NCT06307093 2024-03-12
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
R-Pharm
Phase 1 Active not recruiting
NCT04149691 2024-02-07
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
Celon Pharma SA
Phase 1 Unknown
NCT05969041 2024-01-18
MYE Symphony
Myeloid Therapeutics
Phase 1 Recruiting
NCT01421524 2023-12-12
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Celgene
Phase 1 Completed
NCT05498597 2023-10-19
AMT-151 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics Inc.
Phase 1 Unknown
NCT04990037 2023-06-29
CAPAFOUR
Cantargia AB
Phase 1 Completed
NCT05153408 2023-06-18
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT04363242 2023-04-12
A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions
Synermore Biologics Co., Ltd.
Phase 1 Unknown
NCT03420742 2023-01-27
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Takeda
Phase 1 Completed
NCT02437916 2022-11-08
Safety Study of AMG 228 to Treat Solid Tumors
Amgen
Phase 1 Terminated
NCT04596033 2022-07-15
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Phase 1 Terminated
NCT03852511 2022-06-24
FORTITUDE
Akamis Bio
Phase 1 Completed
NCT02636036 2021-11-09
SPICE
Akamis Bio
Phase 1 Completed
NCT01353625 2021-10-05
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Celgene
Phase 1 Completed
NCT04419623 2021-05-12
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
Telios Pharma, Inc.
Phase 1 Completed
NCT02029690 2020-09-25
TRAP
Polaris Group
Phase 1 Terminated
NCT01999972 2020-09-24
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT02507544 2020-05-21
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
TaiRx, Inc.
Phase 1 Completed
NCT01587703 2020-03-16
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
GlaxoSmithKline
Phase 1 Completed
NCT00097903 2020-03-12
Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer
BioNumerik Pharmaceuticals, Inc.
Phase 1 Completed
NCT02529995 2020-02-11
AURAChinaPK
AstraZeneca
Phase 1 Completed
NCT01295827 2019-12-13
KEYNOTE-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00862355 2019-05-03
Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer
Sun Pharma Advanced Research Company Limited
Phase 1 Completed
NCT00403052 2019-04-16
A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
Dynavax Technologies Corporation
Phase 1 Terminated
NCT03908840 2019-04-09
Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma
Evolve Biologics
Phase 1 Unknown
NCT02703298 2019-03-28
Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients
TaiRx, Inc.
Phase 1 Completed
NCT02454478 2019-03-19
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Eisai Inc.
Phase 1 Completed
NCT00726583 2018-05-17
Phase I Trial of Oral PX-866
Seagen Inc.
Phase 1 Completed
NCT01207323 2018-05-01
A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors
Genentech, Inc.
Phase 1 Completed